Compare · DHR vs MDT
DHR vs MDT
Side-by-side comparison of Danaher Corporation (DHR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- DHR operates in Industrials, while MDT operates in Health Care - the two are in different parts of the market.
- DHR is the larger of the two at $147.18B, about 1.3x MDT ($114.45B).
- Over the past year, DHR is up 4.0% and MDT is down 2.7% - DHR leads by 6.7 points.
- DHR has been more active in the news (20 items in the past 4 weeks vs 14 for MDT).
- Both have 25 recent analyst ratings on file.
- Company
- Danaher Corporation
- Medtronic plc.
- Price
- $207.75-0.75%
- $90.25+0.95%
- Market cap
- $147.18B
- $114.45B
- 1M return
- +3.77%
- +7.98%
- 1Y return
- +3.98%
- -2.71%
- Industry
- Industrial Machinery/Components
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 20
- 14
- Recent ratings
- 25
- 25
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest DHR
- Executive Vice President Riley Christopher Paul was granted 41,072 shares, increasing direct ownership by 201% to 61,472 units (SEC Form 4)
- SEC Form 4 filed by EVP & Chief Financial Officer Gugino Matthew E
- SEC Form 4 filed by SVP-Chief Legal Officer Leiken Jonathan
- SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 13,477 shares, increasing direct ownership by 71% to 32,495 units (SEC Form 4)
- SEC Form 4 filed by Executive Vice President Sawyer Montgomery Julie A
- SEC Form 4 filed by VP, Chief Accounting Officer Bouda Christopher
- Executive Vice President Milosevich Gregory M was granted 15,402 shares, increasing direct ownership by 170% to 24,467 units (SEC Form 4)
- Chairman of Exec. Committee Rales Mitchell P was granted 500,000 shares, increasing direct ownership by 939% to 553,228 units (SEC Form 4)
- Chairman Rales Steven M was granted 500,000 shares, increasing direct ownership by 16% to 3,605,808 units (SEC Form 4)
- SEC Form 4 filed by Director Zerhouni Elias A.
Latest MDT
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)
- EVP & Chief Financial Officer Pieton Thierry was granted 11,537 units of Ordinary Shares, increasing direct ownership by 30% to 49,645 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael was granted 57,107 units of Ordinary Shares and covered exercise/tax liability with 3,356 units of Ordinary Shares, increasing direct ownership by 84% to 117,420 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 3,074 units of Ordinary Shares and was granted 9,230 units of Ordinary Shares, increasing direct ownership by 16% to 43,669 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey was granted 41,533 units of Ordinary Shares and covered exercise/tax liability with 15,810 units of Ordinary Shares, increasing direct ownership by 9% to 327,866 units (SEC Form 4)